Cibus is a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties. Cibus is a leader in the new era of gene-edited trait development, where plant traits (or specific genetic characteristics) that are indistinguishable from traits developed using traditional breeding are now created using gene editing. A key element of Cibus’ technology breakthrough is its patented RTDS® technology platform: the Trait Machine™— the industry’s first semi-automated stand-alone trait production facility. Cibus’ Trait Machine™ materially changes the speed, breadth and scale of trait development. This breakthrough is central to Cibus’ vision for the Future of Breeding: “High Throughput Gene Editing Systems operating as an extension of seed company breeding programs”. The ability to develop complex traits at a fraction of the time and cost of conventional breeding will be critical for addressing the sustainability challenges presented by Climate Change.
Company profile
Ticker
CBUS
Exchange
Website
CEO
James A. Blome
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Calyxt, Inc.
SEC CIK
Corporate docs
Subsidiaries
Ridge Road, LLC ...
CBUS stock data
Latest filings (excl ownership)
8-K
Other Events
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Cibus Reports Fourth Quarter Financial Results and Provides Business Update
21 Mar 24
8-K
Results of Operations and Financial Condition
8 Mar 24
8-K
Cibus Announces Major Breakthrough in Wheat Regeneration from Single Cells
9 Jan 24
8-K
Entry into a Material Definitive Agreement
2 Jan 24
424B5
Prospectus supplement for primary offering
2 Jan 24
8-K
Entry into a Material Definitive Agreement
29 Dec 23
8-K
Other Events
14 Dec 23
424B5
Prospectus supplement for primary offering
12 Dec 23
Transcripts
CBUS
Earnings call transcript
2023 Q4
21 Mar 24
CBUS
Earnings call transcript
2023 Q3
9 Nov 23
CBUS
Earnings call transcript
2023 Q2
10 Aug 23
CBUS
Earnings call transcript
2022 Q3
3 Nov 22
CBUS
Earnings call transcript
2022 Q3
3 Nov 22
CBUS
Earnings call transcript
2022 Q2
7 Aug 22
CBUS
Earnings call transcript
2022 Q2
4 Aug 22
CBUS
Earnings call transcript
2022 Q1
8 May 22
CBUS
Earnings call transcript
2022 Q1
5 May 22
CBUS
Earnings call transcript
2021 Q4
4 Mar 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 31.88 mm | 31.88 mm | 31.88 mm | 31.88 mm | 31.88 mm | 31.88 mm |
Cash burn (monthly) | 6.34 mm | (no burn) | 11.51 mm | 5.31 mm | 5.02 mm | 2.75 mm |
Cash used (since last report) | 42.20 mm | n/a | 76.63 mm | 35.37 mm | 33.46 mm | 18.29 mm |
Cash remaining | -10.31 mm | n/a | -44.75 mm | -3.49 mm | -1.57 mm | 13.60 mm |
Runway (months of cash) | -1.6 | n/a | -3.9 | -0.7 | -0.3 | 5.0 |
Institutional ownership, Q3 2023
43.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 33 |
Opened positions | 13 |
Closed positions | 8 |
Increased positions | 6 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 86.33 bn |
Total shares | 9.19 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
FMR | 2.50 mm | $45.48 bn |
JPL Investments | 1.69 mm | $53.14 mm |
Riggs Rory B | 1.62 mm | $51.18 mm |
Vantage Consulting | 1.26 mm | $23.01 bn |
Mark Terrence Finn | 1.14 mm | $36.03 mm |
BLK Blackrock | 202.92 k | $3.70 bn |
Vanguard | 192.91 k | $3.51 bn |
Geode Capital Management | 147.46 k | $2.69 bn |
CI Private Wealth | 121.72 k | $2.22 bn |
Glenview Capital Management | 119.96 k | $2.19 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Dec 23 | Riggs Rory B | Class A Common Stock | Conversion | Acquire C | No | No | 0 | 1,500,000 | 0.00 | 3,103,788 |
29 Dec 23 | Riggs Rory B | Class B Common Stock | Conversion | Dispose C | No | No | 0 | 1,500,000 | 0.00 | 1,367,193 |
29 Dec 23 | Riggs Rory B | Class B Common Stock | Other | Acquire J | No | No | 0 | 1,505,967 | 0.00 | 2,867,193 |
29 Dec 23 | Riggs Rory B | Cibus Common Units Class A Common Stock | Conversion | Dispose C | No | No | 0 | 1,500,000 | 0.00 | 1,367,193 |
29 Dec 23 | Riggs Rory B | Cibus Common Units Class A Common Stock | Other | Acquire J | No | No | 0 | 1,505,967 | 0.00 | 2,867,193 |
12 Dec 23 | Riggs Rory B | Class A Common Stock | Buy | Acquire P | No | No | 10.58 | 517,107 | 5.47 mm | 1,622,495 |
12 Dec 23 | Riggs Rory B | Pre-Funded Warrant Class A Common Stock | Other | Acquire J | No | No | 10.57 | 50,000 | 528.50 k | 50,000 |
27 Sep 23 | Riggs Rory B | Class A Common Stock | Other | Dispose J | Yes | No | 0 | 39,476 | 0.00 | 1,105,388 |
Press releases
Cibus Reports Fourth Quarter Financial Results and Provides Business Update
21 Mar 24
Cibus to Participate in the 36th Annual Roth Conference
13 Mar 24
Cibus to Report Fourth Quarter 2023 Financial Results on March 21, 2024 and Host Conference Call
7 Mar 24
European Parliament Votes to Support Proposal for the Regulation of New Genomic Techniques
7 Feb 24
Thinking about buying stock in Psyence Biomedical, Micron Technology, Conservative Broadcast Media Journalism, Qualcomm, or Cibus?
7 Feb 24